CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Biosimilars  /  Our work in Biosimilars

BIOCON BIOSIMILARS

Our work in Biosimilars

null

Biocon Biologics is a subsidiary of Biocon with a focus on Biocon’s Biosimilars business. It has one of the largest global biosimilars portfolios spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies and other biologics for  oncology, immunology and other therapeutic areas. We are well positioned to offer lowered costs and increasing access to this highly innovative class of drugs. The demand for biosimilars is set to grow as patents expire on leading biologics and patients demand lower priced drugs.

We have the full spectrum of insulins (regular, basal and rapid) in our pipeline and the global scale necessary to make a difference to diabetes patients worldwide.

We have the full spectrum of insulins (regular, basal and rapid) in our pipeline and the global scale necessary to make a difference to diabetes patients worldwide. Our Biosimilar Monoclonal Antibodies programs which focus on oncology, autoimmune diseases and other areas, will help leverage our position in these chronic segments. We are already making a difference in emerging markets with our Biosimilar Recombinant Human Insulin, which is approved in over 40 countries.

Biosimilars portfolio straddles rh-insulin, insulin analogs, mAbs and other recombinant proteins.

28 products in pipeline. Positioned among early wave of entrants with multiple biosimilars commercialised globally.

15+ years of experience in developing biologics with strong scientific and technical capabilities.

Over 4,500+ people dedicated to support this business across various functions.

6 biosimilars commercialised so far – Trastuzumab, Pegfilgrastim, Bevacizumab, rh-Insulin, Insulin Glargine, Adalimumab.

2+ billion doses cumulatively of biosimilar insulins provided to patients globally.

~2.1 million* patients served globally through our biosimilars in FY20.

Aiming to impact ~5 million* patient lives worldwide in FY22.

*Number of lives is calculated based on volume supplied

CORPORATE GOVERNANCE
KEY THERAPEUTIC AREAS
RESEARCH SERVICES
OUR CULTURE
RESPONSIBILITY
Share